-
公开(公告)号：US20240358702A1
公开(公告)日：2024-10-31
申请号：US18638034
申请日：2024-04-17
申请人： INCYTE CORPORATION
发明人： Onur ATASOYLU , Peter Carlsen , Bin HU , Chengtsung Lai , Matthew McCammant , Alexander Sokolsky , Xiaozhao Wang
IPC分类号： A61K31/513 , A61P35/00 , C07D239/10
CPC分类号： A61K31/513 , A61P35/00 , C07D239/10
摘要： Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
-
公开(公告)号：US20240350499A1
公开(公告)日：2024-10-24
申请号：US18750999
申请日：2024-06-21
发明人： Maya Ridinger , Mark Erlander
IPC分类号： A61K31/519 , A61K9/00 , A61K31/4745 , A61K31/513 , A61K35/04 , A61K39/00 , A61K45/06 , C07K16/22
CPC分类号： A61K31/519 , A61K9/0053 , A61K31/4745 , A61K31/513 , A61K35/04 , A61K45/06 , C07K16/22 , A61K2039/505 , A61K2039/545
摘要： Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.
-
公开(公告)号：US20240350498A1
公开(公告)日：2024-10-24
申请号：US18750971
申请日：2024-06-21
发明人： Maya Ridinger , Mark Erlander
IPC分类号： A61K31/519 , A61K31/4745 , A61K31/513 , A61K39/395 , A61P35/04
CPC分类号： A61K31/519 , A61K31/4745 , A61K31/513 , A61K39/3955 , A61P35/04
摘要： Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.
-
公开(公告)号：US12121519B2
公开(公告)日：2024-10-22
申请号：US17780397
申请日：2020-11-27
发明人： Zaiqi Wang , Jiangwei Zhang , Jun Jiang , Baoyuan Zhang
IPC分类号： A61P35/00 , A61K31/513 , A61K31/519
CPC分类号： A61K31/513 , A61K31/519 , A61P35/00
摘要： The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.
-
公开(公告)号：US20240343733A1
公开(公告)日：2024-10-17
申请号：US18576940
申请日：2022-07-07
发明人： Kevin M. Guckian , Emily Anne Peterson , Fang Gao , Ryan Evans , Eric Stefan , Jeremy L. Yap , Corey Don Anderson , Morgan Welzel O'Shea , Jae Young M. Ahn , Christopher G. Nasveschuk , James A. Henderson
IPC分类号： C07D487/04 , A61K31/4545 , A61K31/513 , A61K31/519 , C07D401/14 , C07D471/04 , C07D487/10 , C07D519/00
CPC分类号： C07D487/04 , A61K31/4545 , A61K31/513 , A61K31/519 , C07D401/14 , C07D471/04 , C07D487/10 , C07D519/00
摘要： This disclosure relates to compounds of Formula (A): IRAK-L-DSM (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches IRAK to DSM; and IRAK is an IRAK4 binding moiety represented by Formula (I) that is covalently attached to linker L; in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of IRAK4 proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of IRAK4 proteins. The present disclosure also provides methods of treating disorders responsive to modulation of IRAK4 activity and/or degradation of IRAK4 with at least one compound described herein.
-
公开(公告)号：US12102637B2
公开(公告)日：2024-10-01
申请号：US18168221
申请日：2023-02-13
发明人： Jayanthy Jayanth , Kevin C. Spence , Gregory A. McClelland , Anna V. Stepanenko , Tzuchi R. Ju , Xi Shao
IPC分类号： A61K31/513 , A61K9/20 , A61P5/30 , A61P15/00
CPC分类号： A61K31/513 , A61K9/2009 , A61K9/2018 , A61K9/2027 , A61K9/2059 , A61P5/30 , A61P15/00
摘要： The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.
-
公开(公告)号：US12090179B2
公开(公告)日：2024-09-17
申请号：US18159934
申请日：2023-01-26
申请人： Salspera, LLC
发明人： Daniel A. Saltzman
IPC分类号： A61K35/74 , A61K31/513 , A61K31/555 , A61K31/675 , A61K31/7068 , A61K33/243
CPC分类号： A61K35/74 , A61K31/513 , A61K31/555 , A61K31/675 , A61K31/7068 , A61K33/243
摘要： A method of treating cancer includes administering a dose of a chemotherapy agent in combination with a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent. The combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.
-
公开(公告)号：US20240299492A1
公开(公告)日：2024-09-12
申请号：US18279451
申请日：2022-03-04
申请人： Shattuck Labs, Inc.
发明人： Taylor SCHREIBER , Suresh DE SILVA , George FROMM
IPC分类号： A61K38/17 , A61K31/282 , A61K31/337 , A61K31/439 , A61K31/454 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/635 , A61K31/69 , A61K31/704 , A61K31/706 , A61K31/7068 , A61K33/243 , A61K38/19 , A61K39/395 , A61K45/06 , A61P35/00
CPC分类号： A61K38/1774 , A61K31/282 , A61K31/337 , A61K31/439 , A61K31/454 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/635 , A61K31/69 , A61K31/704 , A61K31/706 , A61K31/7068 , A61K33/243 , A61K38/191 , A61K39/3955 , A61K45/06 , A61P35/00
摘要： The present disclosure relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer.
-
公开(公告)号：US20240299325A1
公开(公告)日：2024-09-12
申请号：US18667471
申请日：2024-05-17
IPC分类号： A61K31/194 , A61K31/165 , A61K31/17 , A61K31/198 , A61K31/337 , A61K31/475 , A61K31/513 , A61K31/519 , A61K31/52 , A61K31/7048 , A61K31/7056 , A61K31/706 , A61K31/7068 , A61K31/7076 , A61K38/12 , A61P7/00
CPC分类号： A61K31/194 , A61K31/165 , A61K31/17 , A61K31/198 , A61K31/337 , A61K31/475 , A61K31/513 , A61K31/519 , A61K31/52 , A61K31/7048 , A61K31/7056 , A61K31/706 , A61K31/7068 , A61K31/7076 , A61K38/12 , A61P7/00
摘要： The present invention relates to succinic acid and its derivative(s) of Formula (I), their pharmaceutically acceptable salts, polymorphs, solvates, hydrates, co-crystals, isomers and solvates thereof as an active pharmaceutical ingredient for the treatment of haematological disorder(s). The present invention further relates to compounds of Formula (I), for the treatment of disorders selected from dengue, idiopathic thrombocytopeniarpura (ITP), anaemia and chemotherapy induced myelosuppression. The present invention also relates to use of succinic acid for the treatment of haematological disorder(s), wherein succinic acid is extracted from Papaya leaves. The present invention also provides pharmaceutical compositions comprising succinic acid and its derivative(s) of Formula I and methods of treating haematological disorder(s).
-
公开(公告)号：US12083120B2
公开(公告)日：2024-09-10
申请号：US17055067
申请日：2019-05-23
发明人： Ian Hampson , Lynne Hampson
IPC分类号： A61K31/513 , A61K9/00 , A61K9/06 , A61K31/427 , A61K35/00 , A61P35/00
CPC分类号： A61K31/513 , A61K9/0014 , A61K9/06 , A61K31/427 , A61P35/00
摘要： The present invention concerns pharmaceutical compositions formulated for dermal application comprising a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir:ritonavir is between 9:1 and 18:1. Such compositions are useful for treating, or preventing, skin cancers and premalignant dermal conditions.
-
-
-
-
-
-
-
-
-
搜索结果
3809 条记录 (耗时 0.037 秒)
